Price
CHART BY
Frequently asked questions
What is Abcellera's market capitalization?
The market capitalization of Abcellera is $841.79M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Abcellera?
Abcellera's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.60. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Abcellera's stock?
Currently, 9 analysts cover Abcellera's stock, with a consensus target price of $12.29. Analyst ratings provide insights into the stock's expected performance.
What is Abcellera's revenue over the trailing twelve months?
Over the trailing twelve months, Abcellera reported a revenue of $32.96M.
What is the EBITDA for Abcellera?
Abcellera's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$215.86M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Abcellera?
Abcellera has a free cash flow of -$195.27M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Abcellera have, and what sector and industry does it belong to?
Abcellera employs approximately 586 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Abcellera's shares?
The free float of Abcellera is 221.93M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $841.79M
- EPS (TTM)
- -$0.60
- Free Float
- 221.93M
- Revenue (TTM)
- $32.96M
- EBITDA (TTM)
- -$215.86M
- Free Cashflow (TTM)
- -$195.27M
Pricing
- 1D span
- $2.813$2.924
- 52W span
- $2.34$6.05
Analyst Ratings
The price target is $12.29 and the stock is covered by 9 analysts.
Buy
8
Hold
1
Sell
0
Information
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
- Employees
- 586
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- CA00288U1066
- Primary Ticker
- ABCL